Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone913-353-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$35.41 million
Profitability
Miscellaneous
Employees83
Next Earnings DateN/A
OptionableOptionable
Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions
What is Aratana Therapeutics' stock symbol?
Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."
How were Aratana Therapeutics' earnings last quarter?
Aratana Therapeutics Inc (NASDAQ:PETX) released its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. View Aratana Therapeutics' Earnings History.
What price target have analysts set for PETX?
4 analysts have issued 12-month target prices for Aratana Therapeutics' stock. Their forecasts range from $4.14 to $5.00. On average, they anticipate Aratana Therapeutics' share price to reach $4.7250 in the next twelve months. This suggests that the stock has a possible downside of 4.0%. View Analyst Price Targets for Aratana Therapeutics.
What is the consensus analysts' recommendation for Aratana Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics.
Has Aratana Therapeutics been receiving favorable news coverage?
News stories about PETX stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aratana Therapeutics earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Aratana Therapeutics.
Who are some of Aratana Therapeutics' key competitors?
Some companies that are related to Aratana Therapeutics include Stoke Therapeutics (STOK), Zymeworks (ZYME), Omeros (OMER), Cara Therapeutics (CARA), Spectrum Pharmaceuticals (SPPI), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ANI Pharmaceuticals (ANIP), Axsome Therapeutics (AXSM), OrganiGram (OGI), ZIOPHARM Oncology (ZIOP), Emisphere Technologies (EMIS), Kura Oncology (KURA), Arvinas (ARVN) and Alder Biopharmaceuticals (ALDR).
What other stocks do shareholders of Aratana Therapeutics own?
Who are Aratana Therapeutics' key executives?
Aratana Therapeutics' management team includes the folowing people:
- Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)
- Ms. Rhonda L. Hellums, CFO & Treasurer (Age 47)
- Mr. John C. Ayres J.D., VP of Corp. Devel. and Admin., Gen. Counsel & Sec. (Age 40)
- Mr. Brent A. Standridge, Consultant (Age 61)
- Ms. Rachel Reiff, Head of Corp. Communications
Who are Aratana Therapeutics' major shareholders?
Aratana Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.63%), Man Group plc (5.58%), Alpine Associates Management Inc. (4.89%), Water Island Capital LLC (2.90%), Vanguard Group Inc. (2.74%) and OMERS ADMINISTRATION Corp (2.03%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, John C Ayres and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.
Which major investors are selling Aratana Therapeutics stock?
PETX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Bank of Montreal Can, State Board of Administration of Florida Retirement System and BNP Paribas Arbitrage SA. Company insiders that have sold Aratana Therapeutics company stock in the last year include Ernst Heinen, John C Ayres and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.
Which major investors are buying Aratana Therapeutics stock?
PETX stock was purchased by a variety of institutional investors in the last quarter, including Man Group plc, Alpine Associates Management Inc., Water Island Capital LLC, OMERS ADMINISTRATION Corp, Gabelli Funds LLC, Polar Asset Management Partners Inc., GABELLI & Co INVESTMENT ADVISERS INC. and SG Americas Securities LLC. View Insider Buying and Selling for Aratana Therapeutics.
How do I buy shares of Aratana Therapeutics?
Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aratana Therapeutics' stock price today?
One share of PETX stock can currently be purchased for approximately $4.92.
How big of a company is Aratana Therapeutics?
Aratana Therapeutics has a market capitalization of $241.08 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.View Additional Information About Aratana Therapeutics.
What is Aratana Therapeutics' official website?
How can I contact Aratana Therapeutics?
Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]
MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
